Optimizing Perfusion Parameters for Intensified Production of CAR-T Cells in Ambr® 250 High-Throughput Bioreactor

This webcast features: Julia Hengst, PhD, External Collaborations Manager, Cell Culture Technologies, Sartorius.

The demonstrated efficacy of chimeric antigen receptor CAR-T cells against hematological malignancies has led to an increasing number of approved products and further research into additional indications.

Despite recent advances, reaching therapeutic doses using ex vivo expansion of patient CAR-T cells remains challenging and represents the longest phase of manufacturing. Scalable expansion processes that maximize CAR-T cell growth are therefore required to reduce vein-to-vein time and support increasing demand with regards to allogeneic modalities.

Key Takeaways:

Just fill out the form below to watch the recorded webcast now.